breast cancer have a twofold to sixfold greater risk of developing contralateral breast cancer than women in the gen-eral population have of developing a first breast cancer. Tamoxifen therapy reduces this risk, but it is unclear if this benefit exists for both estrogen recep-tor (ER)-positive and ER-negative con-tralateral tumors. Methods: Using data from a population-based tumor regis-try that collects information on the ER status of breast tumors, we followed 8981 women residing in western Wash-ington State who were diagnosed with a primary unilateral invasive breast can
The risk for asynchronous contralateral breast cancer is two to six times greater than the risk for ...
Abstract Background Treatment with tamoxifen or chemo...
Prophylactic treatment with the anti-estrogen tamoxifen may reduce the risk of breast cancer because...
breast cancer by approximately 30%–50%, with benefits probably limited to women with estrogen recept...
Compared with the breast cancer risk women in the general population have, breast cancer survivors h...
BACKGROUND: It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is as...
It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is associated wit...
BackgroundResults from randomized trials indicate that treatment with tamoxifen or chemotherapy for ...
BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hor...
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of similar to 80%, and...
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with ...
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with ...
Of the nearly 185 000 US women who were expected to develop breast cancer in 2009 and the more than ...
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of ∼80%, and following...
Abstract Background Previous population-based studies...
The risk for asynchronous contralateral breast cancer is two to six times greater than the risk for ...
Abstract Background Treatment with tamoxifen or chemo...
Prophylactic treatment with the anti-estrogen tamoxifen may reduce the risk of breast cancer because...
breast cancer by approximately 30%–50%, with benefits probably limited to women with estrogen recept...
Compared with the breast cancer risk women in the general population have, breast cancer survivors h...
BACKGROUND: It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is as...
It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is associated wit...
BackgroundResults from randomized trials indicate that treatment with tamoxifen or chemotherapy for ...
BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hor...
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of similar to 80%, and...
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with ...
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with ...
Of the nearly 185 000 US women who were expected to develop breast cancer in 2009 and the more than ...
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of ∼80%, and following...
Abstract Background Previous population-based studies...
The risk for asynchronous contralateral breast cancer is two to six times greater than the risk for ...
Abstract Background Treatment with tamoxifen or chemo...
Prophylactic treatment with the anti-estrogen tamoxifen may reduce the risk of breast cancer because...